Navigation Links
Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
Date:5/14/2008

in a prestigious, clinically oriented, peer-reviewed publication."

Results from Regado's 1c study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

In the Phase 1c clinical study, the researchers randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The Phase 1 program included two additional studies. A Phase 1a study enrolled 84 healthy volunteers, while a Phase 1b study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results showed an IV bolus injection of RB006 achieved, in both study populations, a prompt, consistent, and dose-dependent prolongation of activated partial thromboplastin time (aPTT). In addition, a 1 mg/kg dose of RB006 resulted in essentially complete Factor IXa inhibition. The studies also demonstrated an IV bolus injection of RB007 administered in a 2:1 antidote:drug ratio successfully reversed prolonged aPTT within a median of one minute, with no rebound increase up to seven days. Despite dual antiplatelet use in 19 subjects, there were no major bleeding or other serious adverse events observed in either study.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon an
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
2. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
3. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
4. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
5. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
6. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... The global aptamers market is expected to reach ... of 17.89% between 2015 and 2020. The aptamer type segments included in this ... report is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... to lower barriers to innovation in life science R&D, has attracted a number ... quarter include another top ten pharmaceutical company joining as a Core member, and ...
(Date:7/6/2015)... July 6, 2015  Approximately 1% of the population ... their chromosomes. These individuals are three times more likely ... in one of the nation,s leading medical journals by ... Canada.  Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... (HHV-6) causes roseola (also known as "sixth disease") and ...
(Date:7/6/2015)... 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused ... Viveve,s Chief Executive Officer, and Scott Durbin , Viveve,s ... 9, 2015. , , , DATE:    , ... , TIME:     , , , 12:15 PM EDT ... http://tinyurl.com/viveve   ,    ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5Pistoia Alliance Continues to Attract New Members 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3
... management product is a hot holiday gift for 2008. Now available ... ... (Vocus) November 20, 2008 -- BodyMedia, Inc. , a pioneer ... GoWear® fit - a lifestyle and calorie management system ...
... Inc., http://www.microphage.com , today announced it has concluded its ... $11 million. Investors in,this round were a combination ... have come from private investors. , ... financing to complete the validation,and launch preparation of their ...
... Nov. 20 WWMR, Inc., the marketing research,leader ... "Most Appreciated Pain,Drug Company Survey". The top ... Endo Pharmaceuticals, according to the 100 pain clinic,physicians ... most noted for,their knowledgeable, respectful and informed sales ...
Cached Biology Technology:BodyMedia, Inc. Launches GowearFit, the First Direct-to-Consumer Lifestyle and Calorie Management System 2BodyMedia, Inc. Launches GowearFit, the First Direct-to-Consumer Lifestyle and Calorie Management System 3MicroPhage Closes Latest Financing 2WWMR Announces Pain Clinic Physicians' Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals 2WWMR Announces Pain Clinic Physicians' Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals 3
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... revealed what may well be the first pervasive rule ... the Proceedings of the National Academy of Sciences researchers ... to become increasingly more complex. Looking back ... catalogue to the present day, the team investigated the ...
... not only smart, but they also wage a good ... studies have shown that plants can sense attacks by ... been known what happens between the pathogen attacks and ... revealed a very complex process that explains how plants ...
... holds three patents in the emerging field of nanotechnology ... the technology,s potential in materials science and medicine. ... a strong call for exploring potential environmental and health ... designing new materials with reduced hazard. The available data, ...
Cached Biology News:First 'rule' of evolution suggests that life is destined to become more complex 2Researcher discovers pathway plants use to fight back against pathogens 2Think green, UO's Hutchison says, to reduce nanotech hazards 2Think green, UO's Hutchison says, to reduce nanotech hazards 3
Sulfadimethoxine (CH-2027)...
... monoclonal [E12] to MAP1 Light Chain MAP1A ... physical interactions between microtubules and components of the ... heavy chain subunit and multiple light chain subunits. ... of the light chain subunits and can associate ...
... system is designed for multiple user laboratories ... for TLC applications. The MultiDoc-It is available ... enclosure provides a darkroom environment and protects ... Use image capture and enhancement , ...
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Biology Products: